Washington — The Trump administration on Monday urged a federal district court to dismiss a lawsuit challenging the Food and Drug Administration's actions expanding access to the widely used abortion pill mifepristone. Justice Department lawyers wrote in a filing with the U.S. district court in Amarillo, Texas, that the three states pursuing the lawsuit — Missouri, Idaho and Kansas — should not be able to do so in that court.
Main Idea: The Trump administration asked a federal judge to dismiss a states’ lawsuit that seeks to roll back FDA rules making the abortion pill mifepristone easier to get.
Key Points:
The lawsuit could keep mifepristone access in legal limbo, leaving patients and clinics unsure about rules for abortion care and mail delivery.
Dismissing the case could reduce court fights and give the FDA clearer room to keep the drug available under current rules.
Rate how each entity in this article affected the American people.
Central governing actor urging the court to dismiss the states’ lawsuit over mifepristone access.
Filed the motion on behalf of the Trump administration and is the main institutional actor in the court.
The agency whose actions expanding access to mifepristone are the subject of the lawsuit.
One of the three states pursuing the lawsuit and a central party in the filing.
One of the three states pursuing the lawsuit and a central party in the filing.
One of the three states pursuing the lawsuit and a central party in the filing.
Comments here are the same thread shown when this article appears in The Pulse.
No comments on this article yet.
Sign in to commentIts prior unanimous ruling on standing is a key part of the article’s legal background.
Named judge overseeing the case, central to the procedural posture of the article.
The court where the case is being litigated and where the dismissal/transfer request is directed.
Oversees the FDA and is part of the administration’s policy chain on the abortion pill.
Health and Human Services secretary quoted and referenced for his role in reviewing mifepristone safety.